Skip to main content
. 2023 Oct 17;13:1244341. doi: 10.3389/fonc.2023.1244341

Figure 1.

Figure 1

Flowchart of the patient selection process. HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; T+L+C, transarterial chemoembolization combined with lenvatinib plus camrelizumab; T+C, transarterial chemoembolization combined with camrelizumab; TACE, transarterial chemoembolization.